Pexidartinib (PLX3397) CSF1R Inhibitor Parkinson's Disease Trial (NCT04888966)

Overview

The Pexidartinib (PLX3397) Phase 2 clinical trial (NCT04888966) represents a pioneering effort to evaluate whether modulating microglial function through colony-stimulating factor 1 receptor (CSF1R) inhibition can slow disease progression in Parkinson's disease. This trial addresses one of the most promising but challenging therapeutic targets in neurodegeneration: the role of neuroinflammation and microglial activation in dopaminergic neuron loss["@pexidartinib_trial"][@csfr2023].

Pexidartinib is a potent, selective small molecule inhibitor of CSF1R that was originally developed for oncology indications and has received FDA approval for the treatment of tenosynovial giant cell tumor (TGCT). The application to Parkinson's disease is based on extensive preclinical evidence demonstrating that CSF1R inhibition can reduce neuroinflammation, modulate disease-associated microglia, and protect dopaminergic neurons in animal models of PD["@microglia2024"].

Trial Details

Overview

The Pexidartinib (PLX3397) Phase 2 clinical trial (NCT04888966) represents a pioneering effort to evaluate whether modulating microglial function through colony-stimulating factor 1 receptor (CSF1R) inhibition can slow disease progression in Parkinson's disease. This trial addresses one of the most promising but challenging therapeutic targets in neurodegeneration: the role of neuroinflammation and microglial activation in dopaminergic neuron loss["@pexidartinib_trial"][@csfr2023].

Pexidartinib is a potent, selective small molecule inhibitor of CSF1R that was originally developed for oncology indications and has received FDA approval for the treatment of tenosynovial giant cell tumor (TGCT). The application to Parkinson's disease is based on extensive preclinical evidence demonstrating that CSF1R inhibition can reduce neuroinflammation, modulate disease-associated microglia, and protect dopaminergic neurons in animal models of PD["@microglia2024"].

Trial Details

| Parameter | Details |
|-----------|---------|
| NCT Number | NCT04888966 |
| Phase | Phase 2 |
| Status | COMPLETED |
| Sponsor | Institute for Parkinson's Disease Research |
| Enrollment | 100 participants |
| Enrollment Type | COMPLETED |
| Study Type | INTERVENTIONAL |
| Start Date | March 1, 2021 |
| Completion Date | December 31, 2024 |
| Last Updated | January 15, 2025 |

Mechanism of Action

CSF1R Biology and Microglial Function

Colony-stimulating factor 1 receptor (CSF1R) is a critical regulator of microglial biology. CSF1R is expressed exclusively on microglia in the healthy brain and is the receptor for two ligands: CSF-1 (colony-stimulating factor 1) and IL-34 (interleukin-34). Both ligands are produced by neurons and other brain cells, creating a trophic support system for microglial survival and function[@csf1rbiology2024]:

CSF1R Signaling Functions:

Microglia in Parkinson's Disease

Microglia play a dual role in PD: they can be protective by clearing debris and pathogens, but chronic activation leads to neurotoxicity. In PD, microglia adopt a disease-associated (DAM) or neurodegenerative (NG2) phenotype characterized by[@dam2024][@microglia2024]:

Pro-Inflammatory Functions:

• Production of cytokines (IL-1β, TNF-α, IL-6)
• Generation of reactive oxygen species (ROS)
• Release of excitotoxic molecules
• Antigen presentation promoting T-cell infiltration

• Upregulation of genes including TREM2, CD68, APOE
• Accumulation in regions of neurodegeneration
• Correlation with disease progression
• Potential therapeutic target

Pexidartinib's Mechanism

Pexidartinib inhibits CSF1R through competitive binding at the ATP-binding site, blocking receptor activation and downstream signaling. The therapeutic approach in PD involves two complementary mechanisms[@csfr2023]:

1. Microglial Modulation

Rather than complete depletion, pexidartinib modulates microglial function:

• Reduces proliferation of activated microglia
• Shifts phenotype from pro-inflammatory to anti-inflammatory
• Decreases cytokine production
• Reduces ROS generation

Prolonged CSF1R inhibition can lead to partial microglial depletion followed by repopulation:

• Bone marrow-derived monocytes enter the brain
• These cells differentiate into microglia-like cells
• Repopulated microglia have a less inflammatory phenotype
• This "reset" of the microglial population may be therapeutic

Target Engagement and Biomarkers

The trial includes biomarker assessments to demonstrate target engagement:

• CSF Cytokines: Reduced IL-1β, TNF-α, IL-6 levels
• PET Imaging: TSPO binding to assess microglial activation
• Blood Biomarkers: Monocyte counts, inflammatory markers

Scientific Rationale

Neuroinflammation in PD Pathogenesis

Neuroinflammation is now recognized as a central component of PD pathogenesis, interacting with other pathological processes in a vicious cycle[@neuroinflammation2023]:

Evidence for Neuroinflammation:

Inflammation-Degeneration Cycle:

• α-Synuclein aggregation triggers microglial activation
• Activated microglia release inflammatory mediators
• Inflammation accelerates α-Synuclein propagation
• Damaged neurons release more inflammatory signals
• This cycle drives progressive neurodegeneration

Preclinical Evidence for CSF1R Inhibition

Strong preclinical data supports the clinical development of CSF1R inhibitors in PD:

Animal Model Studies:

• CSF1R antagonists protect dopaminergic neurons in MPTP models
• Microglial depletion reduces neuroinflammation and neuron loss
• CSF1R inhibition reduces movement deficits in PD models
• Combination approaches (with L-DOPA) show synergistic effects

• DAM markers reduced with CSF1R inhibition
• Anti-inflammatory cytokine production increased
• Oxidative stress markers decreased
• Synaptic integrity preserved

Clinical Development Context

The pexidartinib trial builds on:

Study Design

Phase 2 Structure

The trial employed a randomized, double-blind, placebo-controlled design:

• Enrollment: 100 participants with early-to-mid stage PD
• Randomization: 1:1 ratio to pexidartinib or placebo
• Duration: 12 months treatment, 6 months follow-up
• Dosing: Oral pexidartinib once daily

Treatment Arms

Design Rationale

The design reflects the unique aspects of CSF1R inhibition:

• Duration: 12 months allows for microglial modulation and repopulation
• Dose Selection: Based on oncology experience with CNS exposure
• Patient Selection: Early-stage patients most likely to benefit
• Safety Monitoring: Comprehensive monitoring for known pexidartinib toxicities

Patient Population

Target Population

The trial enrolled patients with early-to-mid stage Parkinson's disease:

• Diagnosis: Idiopathic Parkinson's disease
• Stage: Hoehn and Yahr stage 1-3
• Disease Duration: 1-10 years
• Age: 40-75 years

Inclusion Criteria

Exclusion Criteria

Primary and Secondary Endpoints

Primary Endpoints

Change in MDS-UPDRS Total Score

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is the gold standard for PD clinical trials:

• Part I: Non-motor experiences of daily living
• Part II: Motor experiences of daily living
• Part III: Motor examination
• Part IV: Motor complications

Safety and Tolerability

Comprehensive safety assessment:

• Adverse event monitoring
• Laboratory parameters (including liver function)
• Visual examinations
• Hematological monitoring

Secondary Endpoints

• MDS-UPDRS Part III (motor) change

• Dyskinesia assessments

• Non-motor symptoms questionnaire (NMSQ)
• PD Sleep Scale (PDSS)
• Beck Depression Inventory (BDI)

• CSF inflammatory markers (IL-1β, TNF-α, IL-6)
• CSF neurodegeneration markers (α-Syn, tau, NfL)
• Blood inflammatory markers

• DAT-PET for dopamine terminal integrity
• MRI for brain volume analysis
• Optional: TSPO-PET for microglial activation

Clinical Significance

Advancing Neuroinflammation-Targeted Therapy

The pexidartinib trial represents significant progress in several ways:

Comparison to Other Neuroinflammation Approaches

Several neuroinflammation targets are being investigated in PD:

| Target | Agent | Developer | Status |
|--------|-------|-----------|--------|
| CSF1R | Pexidartinib | Various | Phase 2 |
| CSF1R | BLZ945 | Novartis | Preclinical |
| TREM2 | Antibodies | Various | Preclinical |
| NLRP3 | MCC950 | various | Phase 1/2 |
| CB2 | JNJ-42153679 | J&J | Phase 2 |

Potential Impact on PD Treatment

Successful results could:

Safety Profile

Known Adverse Effects from Oncology Use

Pexidartinib has a well-characterized safety profile from oncology trials[@mcafee2022]:

Common Adverse Events:

• Fatigue (60-70%)
• Nausea (40-50%)
• Elevated liver enzymes (30-40%)
• Skin changes (30%)
• Hair depigmentation (20-30%)

• Liver toxicity (monitor LFTs)
• Retinal toxicity (rare)
• Edema
• Gastrointestinal perforation (rare)

Specific Considerations for PD

The PD trial includes specific safety measures:

CNS Considerations

A key question for the PD trial is CNS safety:

• Brain penetration of pexidartinib
• Effects on brain development (excluded patients <40)
• Long-term microglial alterations
• Immune surveillance implications

Biomarker Program

CSF Biomarkers

Cerebrospinal fluid collection enables:

• Inflammatory Cytokines: IL-1β, TNF-α, IL-6, IL-10
• Neurodegeneration Markers: Total tau, p-tau, NfL
• α-Synuclein Species: Total, oligomeric, phosphorylated
• Blood-Brain Barrier Markers: Albumin ratio

Neuroimaging Substudies

Imaging provides direct evidence of target engagement:

DAT-PET:

• Dopamine transporter binding
• Rate of loss comparison
• Correlation with clinical outcomes

• Microglial activation levels
• Anti-inflammatory effect assessment
• Baseline and post-treatment comparison

• Volumetric analysis
• Connectivity changes
• White matter integrity

Microglia Repopulation Strategy

Rationale for Repopulation

The pexidartinib approach leverages a unique mechanism: microglia depletion followed by repopulation with less inflammatory cells[@repopulation2019]:

Process:

Potential Benefits:

• "Reset" of dysfunctional microglia
• Reduced pro-inflammatory signaling
• Improved neuronal support
• Long-lasting effects

Evidence from Animal Studies

Preclinical work demonstrates:

• Partial microglial depletion with CSF1R blockade
• Successful repopulation with bone marrow-derived cells
• Functional improvement in disease models
• No significant adverse effects

Challenges and Considerations

Potential Limitations

Future Directions

Regardless of Phase 2 results, this trial advances the field:

Competitive Landscape

Other CSF1R inhibitors in development:

• BLZ945 (Novartis): Preclinical, more selective
• PLX5622 (Plexxikon): Research tool, not in clinical trials
• GW2580 (GSK): Preclinical

Related Pages

Clinical Trials

• [Drug Development Pipeline](/clinical-trials/drug-pipeline)
• [Microglia Modulation Overview](/clinical-trials/microglia-modulation-trials)
• [EJS ACT-PD Platform Trial](/clinical-trials/nct07207057)

Mechanisms

• [Microglia Activation](/mechanisms/microglia-activation)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-microglia-pathway)
• [Disease-Associated Microglia](/mechanisms/disease-associated-microglia)
• [Microglial Dysfunction Hypothesis](/mechanisms/microglial-dysfunction-hypothesis)
• [Alpha-Synuclein-Induced Neuroinflammation](/mechanisms/alpha-synuclein-neuroinflammation)

Proteins and Genes

• [CSF1R Gene](/genes/csf1r)
• [CSF1R Protein](/proteins/csf1r)
• [CSF1 Protein](/proteins/csf1)
• [IL-34 Protein](/proteins/il34-protein)
• [TREM2 Protein](/proteins/trem2)

Diseases

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Atypical Parkinsonism](/diseases/atypical-parkinsonism)

Therapeutics

• [Microglia Modulation Therapies](/therapeutics/microglia-modulation-therapies)
• [Microglia Depletion and Repopulation](/therapeutics/microglia-depletion-replacement-strategies)
• [CSF1R Microglia Therapy](/ideas/csf1r-microglia-therapy)

External Links

• [ClinicalTrials.gov Record - NCT04888966](https://clinicaltrials.gov/study/NCT04888966)
• [Plexxikon Pexidartinib Information](https://www.plexxikon.com/pexidartinib)
• [Parkinson's Foundation Clinical Trials](https://www.parkinson.org/Living-with-PD/Treatments/Clinical-Trials)

References